Alios BioPharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT02569710
- Locations
- 🇬🇧
NHS Greater Glasgow and Clyde Glasgow Royal Infirmary, Glasgow, United Kingdom
🇬🇧Pennine Acute Hospitals Trust, Oldham, United Kingdom
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02512562
- Locations
- 🇫🇷
Biotrial, Rennes, France
First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02510248
- Locations
- 🇫🇷
Biotrial, Rennes, Brittany, France
🇲🇩Arensia, Chisinau, Moldova, Republic of
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT02339207
- Locations
- 🇲🇩
Arensia, Republican Clinical Hospital, Chisinau, Moldova, Republic of
🇫🇷Biotrial, Rennes, Brittany, France
🇬🇪Arensia, Research Institute of Clinical Medicine, Tbilisi, Georgia
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02231671
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
A Study of ALS-008176 in Infants Hospitalized With RSV
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT02202356
- Locations
- 🇺🇸
The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
🇦🇺The Canberra Hospital, Canberra, Australia
🇦🇺Princess Margaret Hospital, Perth, Australia
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: vehicle
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02094365
- Locations
- 🇬🇧
Retroscreen Virology Ltd, London, United Kingdom
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01906164
- Locations
- 🇫🇷
Investigational Site, Rennes, France
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01790100
- Locations
- 🇲🇩
Arensia, Republican Clinical Hospital, Chisinau, Moldova, Republic of
First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01590407
- Locations
- 🇷🇴
Arensia, Bucharest, Romania
🇫🇷Biotrial, Paris, France